Common Food Additive Carrageenan Suppresses GLP-1 Hormone Production in Lab-Grown Gut Cells

Human intestinal L-cells (NCI-H716) were cultured, deprived overnight of glucose and serum, then exposed to high glucose, 10% fetal bovine serum, and λ-carrageenan (1 µg/ml) for 10 minutes, 1 hour, and 24 hours. Proglucagon mRNA expression and GLP-1 secretion were measured and compared to controls. Results were validated in mouse L-cells (STC-1). Secondary effects were tested by exposing co-cultured human intestinal epithelial cells (LS174T) to conditioned media from treated L-cells.

With millions of people now taking GLP-1 receptor agonist drugs for diabetes and obesity, discovering that a common processed food additive can suppress the body's own GLP-1 production is significant. Carrageenan is found in many dairy products, plant milks, and processed foods. This study suggests that dietary carrageenan could counteract the effects of GLP-1 medications and impair natural incretin signaling — a finding with direct implications for patients and dietary guidance.

As GLP-1-based peptide drugs become the most prescribed medications for diabetes and obesity, understanding what enhances or inhibits natural GLP-1 production becomes increasingly important. If dietary additives like carrageenan suppress endogenous GLP-1, they could be quietly undermining metabolic health on a population scale — and potentially reducing the effectiveness of expensive peptide medications that millions of patients depend on.

This is entirely an in vitro study using cultured cell lines, which may not accurately replicate the complex gut environment where carrageenan exposure occurs alongside other food components, mucus barriers, and gut microbiota. The carrageenan concentration used (1 µg/ml) may or may not reflect actual intestinal exposure from dietary intake. No human dietary studies were conducted to confirm that eating carrageenan-containing foods actually reduces GLP-1 levels in vivo.